Ian Tomlinson

Ian Tomlinson serves as the Chair at Maxion Therapeutics since April 2022 and has been the Founder Director and SAB Chair at Apollo Therapeutics since February 2016. Tomlinson also holds the position of Chair at Start Codon, established in April 2019, and previously chaired the Stevenage Bioscience Catalyst from September 2015 to September 2020. Prior to these roles, Tomlinson was the Senior Vice President and Head of Worldwide Business Development at GSK from January 2007 to February 2016, where responsibilities included oversight of global business development efforts in pharmaceutical R&D. Tomlinson co-founded Domantis in 2000, serving as EVP and CSO until its acquisition by GSK in 2007, and has a background as a research scientist at the MRC Laboratory of Molecular Biology. Academic qualifications include a Junior Research Fellowship from Trinity College, a PhD from The Open University, and a BA in Zoology from the University of Cambridge.